Navigation Links
New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy
Date:9/24/2008

ibits the rapid firing nerve cells that cause seizures, has been developed to address the need for a new anti-epileptic agent that offers a reduction in seizure frequency combined with a favourable tolerability profile. Zebinix(TM) is currently under review by the EMEA (European Medicines Agency) for the treatment of partial-onset seizures with or without secondary generalisation in combination with other anti-epileptic drugs. A US NDA (New Drug Application) is expected later in 2008 or early 2009.

About the trials

The three phase III, multi-centre, randomised, placebo controlled trials involved more than 1,000 patients from 23 countries. Patients had a history of at least four partial seizures per month despite treatment with up to three concomitant anti-epileptic drugs.(2,3,4)

During the trials, patients were randomised to eslicarbazepine acetate or placebo and after a 2-week titration period, were assessed over a 12 week maintenance period, with continued follow-up over a one year open-label period.(2,3,4,7)

Efficacy

Over the 12 week maintenance period, Zebinix(TM) 800mg and 1200mg reduced seizure frequency by over one third, and was significantly more effective than placebo. This significant decrease in seizure frequency was sustained over the one-year open label treatment period and was consistent regardless of baseline therapy..(2,3,4) Similar positive findings were observed in the responder rate (greater-than-or-equal-to 50% decrease in seizure frequency) for Zebinix(TM) 800mg and 1200mg that ranged between 32% and 43% across all three phase III trials. (2,3,4)

Tolerability

The safety profile of Zebinix(TM) was favourable. The majority of treatment related adverse events were mild or moderate in severity and after 6 weeks, no relevant differences in the incidence of adverse events were apparent between patients treated with eslicarbazepine acetate and patients treated with placebo. In patients treated with Zebi
'/>"/>

SOURCE BIAL
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. MicroRNA First Disclosed by Rosetta Genomics may Increase Efficacy of Imatinib (Gleevec(R)(1)) in Glioblastoma
2. Continuous Treatment With Abbotts HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
3. Interface Biologics Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
4. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
5. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
6. Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First Real World, All Comers Clinical Study
7. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
8. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
9. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
10. Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles
11. Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014  Medical ... laboratory which specializes in high complexity, state-of-the-art, ... is now offering new Cystic Fibrosis Testing ... generation DNA sequencing platforms. Cystic ... inherited multisystem disorder that affects the respiratory, ...
(Date:10/22/2014)... FAIRFIELD, N.J. , Oct. 22, 2014 /PRNewswire/ ... a major transformation in the pain market, according ... Pain Insights, Inc., a firm providing market research ... management. Photo - http://photos.prnewswire.com/prnh/20141021/153440 ... a scheduling change for hydrocodone combination products from ...
(Date:10/22/2014)... October 22, 2014 Investor-Edge has ... (NASDAQ: FOLD ), Progenics Pharmaceuticals Inc. (NASDAQ: ... THLD ), Idera Pharmaceuticals Inc. (NASDAQ: ... research on these five companies can be accessed at: ... 2014, the NASDAQ Composite ended at 4,419.48, up 2.40%, ...
Breaking Medicine Technology:Medical Diagnostic Laboratories, L.L.C. Institute for Biomarker Research Announces New Prenatal Cystic Fibrosis Tests 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5
... and VANCOUVER, April 26, 2007,/PRNewswire-FirstCall/ - Angiotech ... medical device company, announced that,the two-year data ... Wrap(TM) Paclitaxel-Eluting Mesh ("Vascular Wrap(TM)"),will be presented ... The,two-year study examined the safety and efficacy ...
... 26, 2007 - A new study published ... ("A National Survey of,Physician-Industry Relationships") on the ... the need for,profession-wide and public policy reforms ... that the existing,voluntary PhRMA (Pharmaceutical Research and ...
Cached Medicine Technology:Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 2Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 3Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 4Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 5Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 6Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 7Ties Between Physicians and Drug Companies Still Too Strong: the,Prescription Project Offers Solutions to Prevent Conflicts of,Interest 2
(Date:10/22/2014)... Norton HealthDay Reporter , TUESDAY, ... the three Ebola cases in Dallas. But, mental health specialists ... Americans. President Barack Obama on Friday appointed an Ebola ... has infected two Dallas nurses who cared for a Liberian ... Presbyterian Hospital. But the U.S. cases are miniscule in ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 The ... , which is dedicated to distribute health information ... healthcare delivery worldwide announced the development of six ... patients expect when receiving healthcare. These are an ... patient-centered care: “providing care that is respectful of ...
(Date:10/22/2014)... Grants Pass, OR (PRWEB) October 22, 2014 ... while Southern California’s fresh water supply runs dangerously low, ... climate change. Southern Oregon’s rivers, despite the lowest mountain ... fast even in late summer and early autumn.* That ... Urness, authors of the new book “Hiking Southern Oregon,” ...
(Date:10/22/2014)... 2014 Losing Weight Your Body’s Way , ... you in the face, it certainly can be difficult to ... body an extra favor by doing it the healthy way? ... Instead, listen to your body, exercise regularly, and choose foods ... to losing weight; you need to exercise more and eat ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Richard Carlson, ... an industry leader with over 25 years experience. ... leader in the areas related to EDI, B2B Commerce, ... is an Editorial Advisory Board member for Pharmaceutical Commerce ... Blue Fin Group is a management and technology ...
Breaking Medicine News(10 mins):Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2
... is the case with most other developing countries, plastic bags have ... the situation seems to be spiraling out of control, the government ... ,In Uganda they are called buveera , and they ... up at an organized dump like the one at Chitezi in ...
... nonsmoking restaurant and bar employees absorb a potent carcinogennot ... where they had to breathe tobacco smoke from customers ... body only as a result of using tobacco or ... County Health Department and Oregon Department of Human Services ...
... New Delhi, The dry text of science books often despised ... cartoon characters. ,In its recently published science ... Research and Training (NCERT) has introduced two cartoon characters, 'Boojho' ... also on the lookout for answers. ,"Our aim ...
... common joint disorder worldwide, yet the cause of osteoarthritis of ... play a role is femoro-acetabular impingement (FAI), in which the ... on the hip socket (acetabulum). ,FAI caused by ... but it is not known if FAI that is not ...
... statisticians and economists were Saturday winding up four days of ... questions: what is happiness and how do you measure ... for Economic Cooperation and Development acknowledged that the indices used ... as national wealth and Gross Domestic Product, were no longer ...
... given Girls as young as 5 who suffer from cancer ... ,Doctors have extracted, matured and frozen eggs from girls ... up. ,Childhood cancers usually result in cure rates ... which is often needed can render children sterile. The life ...
Cached Medicine News:Health News:Uganda Bans Plastic Bags, Still a Tough Battle Lies Ahead 2Health News:Non Smoking Workers Absorb the Carcinogen Immediately 2Health News:Non Smoking Workers Absorb the Carcinogen Immediately 3Health News:Cartoons to Dispel Science Phobia for Students 2Health News:Osteoarthritis Facts and Causes 2Health News:Experts in Istanbul Seek Nature and Measure of Happiness 2Health News:Girls With Cancer Given Fertility Hope 2
... Worlds First Solid-State Three-Color Photocoagulator.,Retinal physicians ... purchase over 3,000 Lumenis multi-color photocoagulators.,For ... practice, the Novus Varia integrates green, ... a single, compact system that supports ...
... rings, Type 14, 14A and 14C have been ... diameters to accommodate the variations in the size ... capsular tension rings are designed to stabilize the ... a large panel of U.S. ophthalmologists. For ...
Hannum rongeur/grasper with teth in jaws and non-locking design....
Heavy Duty Locking Pliers...
Medicine Products: